{
    "id": 19650,
    "fullName": "PTCH1 loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "PTCH1 loss indicates loss of the PTCH1 gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5727,
        "geneSymbol": "PTCH1",
        "terms": [
            "PTCH1",
            "BCNS",
            "NBCCS",
            "PTC",
            "PTC1",
            "PTCH"
        ]
    },
    "variant": "loss",
    "createDate": "03/14/2016",
    "updateDate": "09/19/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5033,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRT-92 inhibited growth of mouse medulloblastoma cells carrying loss of one copy of the PTCH1 gene (PMID: 25636740).",
            "molecularProfile": {
                "id": 20061,
                "profileName": "PTCH1 loss"
            },
            "therapy": {
                "id": 2418,
                "therapyName": "MRT-92",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2240,
                    "pubMedId": 25636740,
                    "title": "MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25636740"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6324,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Erivedge (vismodegib) and Posaconazole demonstrated enhanced inhibition of Hedgehog signaling in mouse basal cell carcinoma cells harboring PTCH1 loss and TP53 deletion in culture (PMID: 26823493).",
            "molecularProfile": {
                "id": 23083,
                "profileName": "PTCH1 loss TP53 del"
            },
            "therapy": {
                "id": 4114,
                "therapyName": "Posaconazole + Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 2513,
                "name": "basal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5515,
                    "pubMedId": 26823493,
                    "title": "Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26823493"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6266,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Posaconazole inhibited tumor growth in allograft models of basal cell carcinoma derived from mice with heterozygous PTCH1 loss and TP53 knockout (PMID: 26823493).",
            "molecularProfile": {
                "id": 23083,
                "profileName": "PTCH1 loss TP53 del"
            },
            "therapy": {
                "id": 4108,
                "therapyName": "Posaconazole",
                "synonyms": null
            },
            "indication": {
                "id": 2513,
                "name": "basal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5515,
                    "pubMedId": 26823493,
                    "title": "Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26823493"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6323,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Cyclopamine and Posaconazole demonstrated enhanced inhibition of Hedgehog signaling in mouse basal cell carcinoma cells harboring PTCH1 loss and TP53 deletion in culture (PMID: 26823493).",
            "molecularProfile": {
                "id": 23083,
                "profileName": "PTCH1 loss TP53 del"
            },
            "therapy": {
                "id": 4113,
                "therapyName": "Cyclopamine + Posaconazole",
                "synonyms": null
            },
            "indication": {
                "id": 2513,
                "name": "basal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5515,
                    "pubMedId": 26823493,
                    "title": "Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26823493"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20061,
            "profileName": "PTCH1 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23083,
            "profileName": "PTCH1 loss TP53 del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}